Consistency of Primary Cell Collection and Isolation are Critical to Cell Therapy Success

This application note examines how variability in apheresis collection and T cell isolation directly impacts cell therapy manufacturing success, clinical outcomes, and regulatory risk.

Using data from over 55 BioIVT donor leukopaks, it demonstrates that BioIVT’s standardized apheresis collection results in low red blood cell contamination and, when combined with Akadeum’s Human T Cell Leukopak Isolation Kit, delivers consistent T cell purity, viability, and expansion performance.

Together, these factors help reduce manufacturing batch failures and de-risk downstream workflows.

Featured Product: Human T Cell Leukopak Isolation Kit